Memory issues can occur as people age, but what is just a “senior moment” and what is a sign of the onset of dementia?A new ...

“Sundowning is not a type of dementia but a phenomenon that happens to many individuals with dementia later in the day,” explains Adria Thompson, CCC-SLP, a certified dementia practitioner and founder ...

Discover the power of music therapy for dementia. Learn how music can reduce distress and improve well-being in institutional ...

Managing agitation in nursing home patients with Alzheimer ... related dementias requires further understanding. An increased dementia incidence was forecasted to be higher in Hispanic and ...

The trial's new identity reflects its mission to address agitation, a syndrome affecting up to 76% of the 55 million Alzheimer's patients worldwide that also adversely impacts the quality of life ...

Researchers at the University of Kentucky are part of a groundbreaking clinical trial exploring the use of medical marijuana ...

Research into whether interventions can increase engagement in meaningful activity and reduce sedentary behavior among ...

POTOMAC, MD / ACCESSWIRE / January 8, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") announced today that its ongoing Phase 2 trial for agitation in Alzheimer's disease ...

Our lead therapeutic candidate, IGC-AD1, is a cannabinoid-based treatment currently in a Phase 2 trial for agitation in dementia associated with Alzheimer's (clinicaltrials.gov, NCT05543681).